Year All20242023202220212020201920182017201620152014 Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) April 15, 2024 Corcept Completes Enrollment in Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer April 8, 2024 Corcept Completes Enrollment in Phase 3 GRADIENT Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome April 1, 2024 Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update February 15, 2024 Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial February 15, 2024 Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call February 8, 2024 Corcept Appoints Roberto Vieira as President, Oncology January 29, 2024 Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program January 8, 2024 Court Finds Corcept Therapeutics’ Patents Not Infringed January 2, 2024
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) April 15, 2024
Corcept Completes Enrollment in Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer April 8, 2024
Corcept Completes Enrollment in Phase 3 GRADIENT Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome April 1, 2024
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update February 15, 2024
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial February 15, 2024
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call February 8, 2024
Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program January 8, 2024